VASCOR Drug Patent Profile
Which patents cover Vascor, and when can generic versions of Vascor launch?
Vascor is a drug marketed by Johnson And Johnson and Mallinckrodt and is included in two NDAs.
The generic ingredient in VASCOR is iothalamate meglumine; iothalamate sodium. There are two drug master file entries for this compound. Additional details are available on the iothalamate meglumine; iothalamate sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VASCOR?
- What are the global sales for VASCOR?
- What is Average Wholesale Price for VASCOR?
Summary for VASCOR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 1 |
| Patent Applications: | 831 |
| DailyMed Link: | VASCOR at DailyMed |
Recent Clinical Trials for VASCOR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Poznan University of Medical Sciences | Phase 3 |
US Patents and Regulatory Information for VASCOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-001 | Dec 28, 1990 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mallinckrodt | VASCORAY | iothalamate meglumine; iothalamate sodium | INJECTABLE;INJECTION | 016783-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-002 | Dec 28, 1990 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-003 | Dec 28, 1990 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VASCOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-001 | Dec 28, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-003 | Dec 28, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| Johnson And Johnson | VASCOR | bepridil hydrochloride | TABLET;ORAL | 019002-002 | Dec 28, 1990 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VASCOR
See the table below for patents covering VASCOR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 795735 | ⤷ Start Trial | |
| Canada | 1015360 | ETHYLENEDIAMINES SUBSTITUEES A ACTIVITE CARDIOVASCULAIRE | ⤷ Start Trial |
| Canada | 1048027 | ETHYLENEDIAMINES SUBSTITUEES A ACTIVITE CARDIOVASCULAIRE (SUBSTITUTED ETHYLENE DIAMINE WITH CARDIOVASCULAR ACTIVITIES) | ⤷ Start Trial |
| Switzerland | 556815 | PROCEDE POUR LA PREPARATION DES PROPYLAMINES. | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch